生物医学工程学杂志

生物医学工程学杂志

甲状腺癌中 BRAF V600E 的临床价值及端粒酶逆转录酶启动子突变的影响

查看全文

近年来,由于甲状腺癌的发病率越来越高,世界各地的学者开始更多地关注甲状腺癌,对其发病机制、疾病演变及转归预后都进行了探索研究。其中基因分子领域的研究成为热点,如抗鼠科肉瘤病毒癌基因同源物 B1(BRAF)突变和端粒酶逆转录酶(TERT)启动子突变等,但目前相关研究尚不成熟,仍有很多问题及挑战亟待解决。本文从基因分子学理论出发,探究 BRAF 突变在甲状腺乳头状癌的治疗、复发、死亡率及预后评估中的应用价值,以及 BRAF 突变与 TERT 启动子突变在甲状腺癌中的相互联系与影响,以供相关学者了解该领域的现状,为今后进一步研究提供一个大致的方向。

In recent years, the incidence of thyroid cancer has been increasing. Researches around the world have begun to pay more attention to the exploration of its pathogenesis, disease evolution and prognosis. Among them, research in the field of gene molecules has become a hotspot, which includes the mutations of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) and the telomerase reverse transcriptase (TERT) promoter. However, this field is not mature, and there are many problems and challenges need to be solved. This paper explores the value of BRAF mutation in the treatment, recurrence, mortality and prognosis of papillary thyroid carcinoma. In addition, we also explore the relationship between BRAF mutation and TERT promoter mutations and their influences in thyroid cancer. We hope this paper could help later scholars understand the current situation in this field and find a research direction in the future.

关键词: 甲状腺癌; 抗鼠科肉瘤病毒癌基因同源物 B1; 端粒酶逆转录酶

Key words: thyroid carcinoma; v-raf murine sarcoma viral oncogene homologue B1; telomerase reverse transcriptase

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
2. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer, 2015, 136(9): 2187-2195.
3. Miller K D, Siegel R L, LIN C C, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin, 2016, 66(4): 271-289.
4. Rahib L, Smith B D, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 2014, 74(11): 2913-2921.
5. Smittenaar C R, Petersen K A, Stewart K, et al. Cancer incidence and mortality projections in the UK until 2035. Br J Cancer, 2016, 115(9): 1147-1155.
6. Jung Y Y, Yoo J H, Park E S, et al. Clinicopathologic correlations of the BRAF V600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Pathol Res Pract, 2015, 211(2): 162-170.
7. Yuan P, Cao J L, Abuduwufuer A, et al. Clinical characteristics and prognostic significance of TERT promoter mutations in cancer: a cohort study and a meta-analysis. PLoS One, 2016, 11(1): e0146803.
8. Hoang J K, Choudhury K R, Eastwood J D, et al. An exponential growth in incidence of thyroid cancer: trends and impact of CT imaging. AJNR Am J Neuroradiol, 2014, 35(4): 778-783.
9. Brito J P, Kim H J, Han S J, et al. Geographic distribution and evolution of thyroid cancer epidemic in South Korea. Thyroid, 2016, 26(6): 864-865.
10. 宫舒萍, 林少倩, 王莹, 等. 2012-2016 年济南市城市居民恶性肿瘤发病分析. 现代预防医学, 2018, 45(2): 270-272, 307.
11. 黄声稀, 金伟奎, 司芩. 超声造影联合弹性成像诊断甲状腺癌的价值分析. 临床肿瘤学杂志, 2017, 22(9): 823-826.
12. Davies L, Morris L G, Haymart M, et al. American association of clinical endocrinologists and American college of endocrinology disease state clinical review: the increasing incidence of thyroid cancer. Endocr Pract, 2015, 21(6): 686-696.
13. Xu L, Port M, Landi S, et al. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid, 2014, 24(6): 966-974.
14. Sak S D. Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor. Turk Patoloji Derg, 2015, 31(Suppl 1): 34-47.
15. Fraser S, C G O, Aniss A, et al. BRAF(V600E) mutation is associated with decreased disease-free survival in papillary thyroid cancer. World J Surg, 2016, 40(7): 1618-1624.
16. Du L, Wang Y, Sun X, et al. Thyroid cancer: trends in incidence, mortality and clinical-pathological patterns in Zhejiang province, southeast China. BMC Cancer, 2018, 18(1): 291.
17. Vannucchi G, de Leo S, Perrino M, et al. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. Eur J Endocrinol, 2015, 173(1): 29-36.
18. Wang Y, Guo Q, Zhao Y, et al. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett, 2014, 8(5): 1947-1952.
19. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol, 2010, 321(1): 86-93.
20. Zhao H, Zhang Z H, Zhou B, et al. Detection of BRAF c.1799T>A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. Diagn Cytopathol, 2015, 43(10): 786-790.
21. Dyhdalo K, Macnamara S, Brainard J, et al. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples. Cancer Cytopathol, 2014, 122(2): 114-122.
22. 何俊峰, 闫国珍, 刘扬, 等. 甲状腺微小癌超声引导下细针穿刺细胞学与粗针穿刺组织学检查的临床对比研究. 中国超声医学杂志, 2018, (3): 211-213.
23. Sun J, Zhang J, Lu J, et al. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Int J Clin Exp Pathol, 2015, 8(11): 15072-15078.
24. Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta, 1993, 1154(1): 65-82.
25. Xing M, Alzahrani A S, Carson K A, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol, 2015, 33(1): 42-50.
26. Millington G W, Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54). Clin Exp Dermatol, 2013, 38(2): 222-223.
27. Perri F, Pezzullo L, Chiofalo M G, et al. Targeted therapy: a new hope for thyroid carcinomas. Crit Rev Oncol Hematol, 2015, 94(1): 55-63.
28. Rothenberg S M, Mcfadden D G, Palmer E L, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res, 2015, 21(5): 1028-1035.
29. Liu X, Yan K, Lin X, et al. The association between BRAF(V600E) mutation and pathological features in PTC. Eur Arch Otorhinolaryngol, 2014, 271(11): 3041-3052.
30. Vuong H G, Duong U N, Altibi A M, et al. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect, 2017, 6(3): R8-r17.
31. Lee J I, Jang H W, Kim S W, et al. BRAFV600E mutation in fine-needle aspiration aspirates: association with poorer prognostic factors in larger papillary thyroid carcinomas. Head Neck, 2013, 35(4): 548-553.
32. Czarniecka A, Kowal M, Rusinek D, et al. The risk of relapse in papillary thyroid cancer (PTC) in the context of BRAFV600E mutation status and other prognostic factors. PLoS One, 2015, 10(7): e0132821.
33. Kim B H, Kim I J, Lee B J, et al. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med J, 2015, 56(3): 634-640.
34. Lu J, Gao J, Zhang J, et al. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol, 2015, 8(1): 793-799.
35. Yang Libo, Sun Linyong, Jiang Yong, et al. The clinicopathological features of BRAF mutated papillary thyroid cancers in chinese patients. Int J Endocrinol, 2015, 2015: 642046.
36. Heidenreich B, Rachakonda P S, Hemminki K, et al. TERT promoter mutations in cancer development. Curr Opin Genet Dev, 2014, 24: 30-37.
37. Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer, 2016, 23(3): R143-R155.
38. Alzahrani A S, Alsaadi R, Murugan A K, et al. TERT promoter mutations in thyroid cancer. Horm Cancer, 2016, 7(3): 165-177.
39. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol, 2014, 32(25): 2718-2726.